FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149733252> ?p ?o ?g. }

• W2149733252 endingPage "59" @default.
• W2149733252 startingPage "54" @default.
• W2149733252 abstract "BackgroundNEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). Subsequent analysis was carried out mainly regarding overall survival (OS).Materials and methodsFor all 228 patients in NEJ002, survival data were updated in December, 2010. Detailed information regarding subsequent chemotherapy after the protocol treatment was also assessed retrospectively and the impact of some key drugs on OS was evaluated.ResultsThe median survival time (MST) was 27.7 months for the gefitinib group, and was 26.6 months for the CBDCA/PTX group (HR, 0.887; P=0.483). The OS of patients who received platinum throughout their treatment (n=186) was not statistically different from that of patients who never received platinum (n=40). The MST of patients treated with gefitinib, platinum, and pemetrexed (PEM) or docetaxel (DOC, Taxotere; n=76) was around 3 years.ConclusionsNo significant difference in OS was observed between gefitinib and CBDCA/PTX in the NEJ002 study, probably due to a high crossover use of gefitinib in the CBDCA/PTX group. Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended." @default.
• W2149733252 created "2016-06-24" @default.
• W2149733252 creator A5006025910 @default.
• W2149733252 creator A5007143858 @default.
• W2149733252 creator A5011349035 @default.
• W2149733252 creator A5011533142 @default.
• W2149733252 creator A5013199621 @default.
• W2149733252 creator A5017693924 @default.
• W2149733252 creator A5026281541 @default.
• W2149733252 creator A5029655825 @default.
• W2149733252 creator A5037474733 @default.
• W2149733252 creator A5037746646 @default.
• W2149733252 creator A5040162534 @default.
• W2149733252 creator A5043047683 @default.
• W2149733252 creator A5044579640 @default.
• W2149733252 creator A5058088814 @default.
• W2149733252 creator A5060336399 @default.
• W2149733252 creator A5071117344 @default.
• W2149733252 creator A5077670186 @default.
• W2149733252 creator A5080846994 @default.
• W2149733252 creator A5087829407 @default.
• W2149733252 date "2013-01-01" @default.
• W2149733252 modified "2023-10-17" @default.
• W2149733252 title "Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)" @default.
• W2149733252 cites W2009481811 @default.
• W2149733252 cites W2016717983 @default.
• W2149733252 cites W2043587877 @default.
• W2149733252 cites W2043696829 @default.
• W2149733252 cites W2069312070 @default.
• W2149733252 cites W2071161965 @default.
• W2149733252 cites W2093922887 @default.
• W2149733252 cites W2095618958 @default.
• W2149733252 cites W2114461323 @default.
• W2149733252 cites W2119366998 @default.
• W2149733252 cites W2129360604 @default.
• W2149733252 cites W2132157071 @default.
• W2149733252 cites W2134667653 @default.
• W2149733252 cites W2142464801 @default.
• W2149733252 cites W2160040938 @default.
• W2149733252 cites W2161821474 @default.
• W2149733252 cites W2166084034 @default.
• W2149733252 cites W4231599003 @default.
• W2149733252 doi "https://doi.org/10.1093/annonc/mds214" @default.
• W2149733252 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22967997" @default.
• W2149733252 hasPublicationYear "2013" @default.
• W2149733252 type Work @default.
• W2149733252 sameAs 2149733252 @default.
• W2149733252 citedByCount "455" @default.
• W2149733252 countsByYear W21497332522012 @default.
• W2149733252 countsByYear W21497332522013 @default.
• W2149733252 countsByYear W21497332522014 @default.
• W2149733252 countsByYear W21497332522015 @default.
• W2149733252 countsByYear W21497332522016 @default.
• W2149733252 countsByYear W21497332522017 @default.
• W2149733252 countsByYear W21497332522018 @default.
• W2149733252 countsByYear W21497332522019 @default.
• W2149733252 countsByYear W21497332522020 @default.
• W2149733252 countsByYear W21497332522021 @default.
• W2149733252 countsByYear W21497332522022 @default.
• W2149733252 countsByYear W21497332522023 @default.
• W2149733252 crossrefType "journal-article" @default.
• W2149733252 hasAuthorship W2149733252A5006025910 @default.
• W2149733252 hasAuthorship W2149733252A5007143858 @default.
• W2149733252 hasAuthorship W2149733252A5011349035 @default.
• W2149733252 hasAuthorship W2149733252A5011533142 @default.
• W2149733252 hasAuthorship W2149733252A5013199621 @default.
• W2149733252 hasAuthorship W2149733252A5017693924 @default.
• W2149733252 hasAuthorship W2149733252A5026281541 @default.
• W2149733252 hasAuthorship W2149733252A5029655825 @default.
• W2149733252 hasAuthorship W2149733252A5037474733 @default.
• W2149733252 hasAuthorship W2149733252A5037746646 @default.
• W2149733252 hasAuthorship W2149733252A5040162534 @default.
• W2149733252 hasAuthorship W2149733252A5043047683 @default.
• W2149733252 hasAuthorship W2149733252A5044579640 @default.
• W2149733252 hasAuthorship W2149733252A5058088814 @default.
• W2149733252 hasAuthorship W2149733252A5060336399 @default.
• W2149733252 hasAuthorship W2149733252A5071117344 @default.
• W2149733252 hasAuthorship W2149733252A5077670186 @default.
• W2149733252 hasAuthorship W2149733252A5080846994 @default.
• W2149733252 hasAuthorship W2149733252A5087829407 @default.
• W2149733252 hasBestOaLocation W21497332521 @default.
• W2149733252 hasConcept C121608353 @default.
• W2149733252 hasConcept C126322002 @default.
• W2149733252 hasConcept C143998085 @default.
• W2149733252 hasConcept C2776256026 @default.
• W2149733252 hasConcept C2776694085 @default.
• W2149733252 hasConcept C2777240266 @default.
• W2149733252 hasConcept C2777292972 @default.
• W2149733252 hasConcept C2778239845 @default.
• W2149733252 hasConcept C2779438470 @default.
• W2149733252 hasConcept C2780580887 @default.
• W2149733252 hasConcept C2781190966 @default.
• W2149733252 hasConcept C2781451048 @default.
• W2149733252 hasConcept C71924100 @default.
• W2149733252 hasConceptScore W2149733252C121608353 @default.
• W2149733252 hasConceptScore W2149733252C126322002 @default.
• W2149733252 hasConceptScore W2149733252C143998085 @default.
• W2149733252 hasConceptScore W2149733252C2776256026 @default.

• next